CN118339179A - 经修饰的蛋白或多肽 - Google Patents

经修饰的蛋白或多肽 Download PDF

Info

Publication number
CN118339179A
CN118339179A CN202280075005.3A CN202280075005A CN118339179A CN 118339179 A CN118339179 A CN 118339179A CN 202280075005 A CN202280075005 A CN 202280075005A CN 118339179 A CN118339179 A CN 118339179A
Authority
CN
China
Prior art keywords
single variable
immunoglobulin single
variable domain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280075005.3A
Other languages
English (en)
Chinese (zh)
Inventor
王楠
杨晓峰
张伟
曹志亮
叶浩
沈余红
廖成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Shengdi Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN118339179A publication Critical patent/CN118339179A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280075005.3A 2021-11-29 2022-11-29 经修饰的蛋白或多肽 Pending CN118339179A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021114298923 2021-11-29
CN202111429892 2021-11-29
PCT/CN2022/134923 WO2023093899A1 (zh) 2021-11-29 2022-11-29 经修饰的蛋白或多肽

Publications (1)

Publication Number Publication Date
CN118339179A true CN118339179A (zh) 2024-07-12

Family

ID=86538884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280075005.3A Pending CN118339179A (zh) 2021-11-29 2022-11-29 经修饰的蛋白或多肽

Country Status (6)

Country Link
US (1) US20250026842A1 (https=)
EP (1) EP4435002A4 (https=)
JP (1) JP2024543134A (https=)
CN (1) CN118339179A (https=)
TW (1) TW202330596A (https=)
WO (1) WO2023093899A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
SG10201805064SA (en) * 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RS55775B2 (sr) * 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP4707303A2 (en) * 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains
JP7001474B2 (ja) * 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
NO2768984T3 (https=) * 2015-11-12 2018-06-09
CN113621065B (zh) * 2021-08-30 2023-08-01 武汉海沙百得生物技术有限公司 靶向4-1bb的全人源抗体及其制备方法和应用

Also Published As

Publication number Publication date
WO2023093899A1 (zh) 2023-06-01
US20250026842A1 (en) 2025-01-23
JP2024543134A (ja) 2024-11-19
EP4435002A1 (en) 2024-09-25
EP4435002A4 (en) 2025-03-26
TW202330596A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
CN111712518B (zh) 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
KR20220154140A (ko) Pvrig 결합 단백질 및 이의 의학적 용도
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
EP4393950A1 (en) Fap/cd40 binding molecule and medicinal use thereof
AU2019208793A1 (en) Anti-4-1BB antibody, antigen-binding fragment thereof and medical use thereof
EP4403574A1 (en) Protein specifically binding to pd-1 and pharmaceutical use thereof
TWI815136B (zh) 一種雙特異性抗體及其用途
EP4674868A1 (en) Fap/4-1bb/cd40 binding molecule and medicinal use thereof
CA3227854A1 (en) Novel anti-sirpa antibodies
EP4628507A1 (en) Cldn18.2/4-1bb binding protein and medical use thereof
CN118108853A (zh) Cd47/4-1bb结合蛋白及其医药用途
TWI818276B (zh) Fab-HCAb結構的結合蛋白
US20250026842A1 (en) Modified protein or polypeptide
CN116813786B (zh) 抗cd73抗体及其应用
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途
TW202537974A (zh) Ｔｒｇｖ９結合蛋白及其醫藥用途
CA3284183A1 (en) Fap/4-1bb/cd40 binding molecule and medicinal use thereof
WO2026056998A1 (zh) Gipr结合分子及医药用途
CA3274166A1 (en) Cldn18.2/4-1bb binding protein and medical use thereof
CN119546636A (zh) FcRn-结合多肽及其用途
WO2023092048A1 (en) Anti-tnf-alpha antibodies and compositions
CN121712807A (zh) Ctla4/tigit结合蛋白及其医药用途
CN115572330A (zh) 一种特异性抗体及其制备方法和应用
HK40076302A (en) New polypeptide complex
KR20200119846A (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination